Search

Eosinophilic dermatosis of hematologic malignancy (EDHM) is a cutaneous manifestation seen in patients with hematoproliferative and lymphoproliferative disorders, most commonly chronic lymphocytic leukemia. This systematic review aimed to summarize the therapeutic interventions of EDHM. A comprehensive search yielded 71 studies, predominantly case reports and series. The most frequently reported modalities were systemic and topical corticosteroids, as well as treatment of the underlying malignancy. Responses to these treatments varied. Targeted therapies, including dupilumab and omalizumab, showed promise, as did other modalities such as montelukast, dapsone, doxycycline, and phototherapy. Higher‐quality studies should be conducted to facilitate higher‐quality management recommendations for EDHM. [ABSTRACT FROM AUTHOR]

Hyperkeratotic flexural erythema (HKFE) is an uncommon differential diagnosis for intertriginous eruptions.1 Diagnosis is made clinically with a characteristic appearance of erythematous, scaly, peripherally advancing skin lesions arising from flexural areas. The clinical presentation was consistent with HKFE, and the patient commenced on amoxicillin-clavulanic acid 875/125 mg twice-daily, petrolatum:liquid paraffin(50:50) emollient, coconut oil and cessation of Canesten wash. In some stages of HKFE, GP is not seen and thus GP is not essential for HKFE diagnosis.2 Furthermore, GP can occur on biopsy without the characteristic appearance of HKFE. [Extracted from the article]

Tocilizumab is a humanized monoclonal antibody to the interleukin-6 (IL-6) receptor which was first approved for use in refractory rheumatoid arthritis almost a decade ago. Since then, its use has expanded to a number of rheumatological and inflammatory conditions. In dermatology, off-label use of tocilizumab has been reported to be efficacious in morphoea, systemic sclerosis, psoriasis, atopic dermatitis, vitiligo, graft-versus-host disease, pyoderma gangrenosum, Behcet's disease, Schnitzler's syndrome, sarcoidosis, and cutaneous adverse reactions. That being said, the evidence demonstrating tocilizumab's efficacy in dermatology is predominantly low-level case-based evidence, and one must consider the potential for publication bias. In this review we will discuss the reported clinical applications of tocilizumab in dermatology, mechanisms of action, and the range of associated adverse effects (both cutaneous and non-cutaneous) that can occur. Additionally, we will discuss the role of tocilizumab in the management of COVID-19., (© 2021 Wiley Periodicals LLC.)